TSX: HSM     OTC: HSDT

Call us: +1 215-809-2018

newsBanner

Helius Medical Technologies Announces Receipt of US$ $2.0 mln from Convertible Credit Facility, Issues Shares and Warrants to A&B Co. Ltd. HK

(Newtown PA) – November 10, 2015 – Helius Medical Technologies, Inc. (CSE: HSM; OTCQB: HSDT) (“Helius”, or the “Company”), a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, advises that it has issued a convertible promissory note for US$2.0 mln to A&B Co. Ltd. HK (the “Note”) as per the Company’s news release dated October 13, 2015. The company has received US$2.0 mln and has elected to immediately satisfy the terms of the note with issuance of 2,083,333 shares and 1,041,667 3-year warrants to A&B Co. Ltd, HK. The shares have a deemed price of US$0.96, which represents a 40% premium to the 20-day volume weighted moving average from the date of signing of the Note, and the exercise price of the warrants is US$1.44. The shares will be subject to a four-month statutory hold period.

Helius can, at the company’s option, draw against any of the remaining US$5.0 mln of the six-month facility and elect to immediately repay with the issuance of shares and warrants at a price scheme agreed to by both parties as allowed by the policies of the Canadian Securities Exchange. All securities issues with respect to the credit facility will be subject to a four-month statutory hold period. Please see the Company’s SEDAR and EDGAR filings for additional details.

The Company also announces that it shall issue 30,000 bonus common shares at a deemed price of US $0.69 per share to a shareholder who advanced a small loan to the Company. The shares will be subject to a four-month statutory hold period.

About the PoNS™

The PoNS™ device is a non-invasive means for delivering neurostimulation through the tongue. The PoNS™ therapy is currently being studied in the United States for the treatment of balance disorder for subjects with mild to moderate Traumatic Brain Injury (“mTBI”), and in Canada for the treatment of gait and balance disorder for subjects with MS.

The PoNS™ device is believed to be the first non-invasive means for delivering neurostimulation through the tongue. Researchers believe that use of the tongue as a gateway to the brain may be one of the most natural, non-invasive and direct ways to stimulate the brain. The tongue is anatomically unique, being richly innervated by thousands of nerve fibers and interconnected to the brainstem by two major cranial nerves.

About Helius Medical Technologies (HMT)

Helius Medical Technologies is a medical technology company focused on neurological wellness. HMT seeks to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. HMT intends to file for U.S. Food and Drug Administration clearance for the PoNS™ device. For more information, please visit www.heliusmedical.com. The contents of this website are not, and should not be deemed to be, incorporated by reference herein.

Cautionary Disclaimer Statement:

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

# # #

Contact:

Corporate Contact:
Phil Deschamps

614-596-2597

pdeschamps@heliusmedical.com

Investor Relations:

778-588-7144

info@heliusmedical.com

Media Contact:

Becky Kern

914-772-2310

media@heliusmedical.com